High Prevalence of Antimicrobial Resistance among Shigella Isolates in the United States Tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002
Open Access
- 1 January 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (1), 49-54
- https://doi.org/10.1128/aac.50.1.49-54.2006
Abstract
Shigella spp. infect approximately 450,000 persons annually in the United States, resulting in over 6,000 hospitalizations. Since 1999, the National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria has tested every 10th Shigella isolate from 16 state or local public health laboratories for susceptibility to 15 antimicrobial agents. From 1999 to 2002, NARMS tested 1,604 isolates. Among 1,598 isolates identified to species level, 1,278 (80%) were Shigella sonnei , 295 (18%) were Shigella flexneri , 18 (1%) were Shigella boydii , and 7 (0.4%) were Shigella dysenteriae . Overall, 1,251 (78%) were resistant to ampicillin and 744 (46%) were resistant to trimethoprim-sulfamethoxazole (TMP-SMX). Prevalence of TMP-SMX- or ampicillin- and TMP-SMX-resistant Shigella sonnei isolates varied by geographic region, with lower rates in the South and Midwest regions (TMP-SMX resistance, 27% and 30%, respectively; ampicillin and TMP-SMX resistance, 25% and 22%, respectively) and higher rates in the East and West regions (TMP-SMX resistance, 66% and 80%, respectively; ampicillin and TMP-SMX resistance, 54% and 65%, respectively). Nineteen isolates (1%) were resistant to nalidixic acid (1% of S. sonnei and 2% of S. flexneri isolates); 12 (63%) of these isolates had decreased susceptibility to ciprofloxacin. One S. flexneri isolate was resistant to ciprofloxacin. All isolates were susceptible to ceftriaxone. Since 1986, resistance to ampicillin and TMP-SMX has dramatically increased. Shigella isolates in the United States remain susceptible to ciprofloxacin and ceftriaxone.Keywords
This publication has 42 references indexed in Scilit:
- Antimicrobial Susceptibility of Shigella sonnei Isolates in Japan and Molecular Analysis of S. sonnei Isolates with Reduced Susceptibility to FluoroquinolonesAntimicrobial Agents and Chemotherapy, 2005
- Nalidixic Acid-Resistant Salmonella enterica Serotype Typhi Presenting as a Primary Psoas Abscess: Case Report and Review of the LiteratureJournal of Clinical Microbiology, 2005
- Increasing incidence of resistance to nalidixic acid in shigellas from humans in England and Wales: implications for therapyClinical Microbiology & Infection, 2004
- CTX-M-3 Extended-spectrum ß-lactamase in a Shigella sonnei Clinical Isolate: First Report from TurkeyScandinavian Journal of Infectious Diseases, 2003
- Third-Generation Cephalosporin Resistance inShigella sonnei, ArgentinaEmerging Infectious Diseases, 2001
- Practice Guidelines for the Management of Infectious DiarrheaClinical Infectious Diseases, 2001
- Food-Related Illness and Death in the United StatesEmerging Infectious Diseases, 1999
- Mutator plasmid in a nalidixic acid-resistant strain of Shigella dysenteriae type 1Journal of Antimicrobial Chemotherapy, 1993
- Interruption of shigellosis by hand washingTransactions of the Royal Society of Tropical Medicine and Hygiene, 1982
- Resistance of Shigella dysenteriae Type 1 to Ampicillin and Other Antimicrobial Agents: Strains Isolated during a Dysentery Outbreak in a Hospital in Mexico CityThe Journal of Infectious Diseases, 1976